Skip to navigation | Skip to main content | Skip to footer
Menu Search the University of Manchester siteSearch
Search type

Alternatively, use our A–Z index

Professor David Denning (FRCP FRCPath DCH FMedSci) - personal details

Contact details

Professor David Denning

Role: Professor of Infectious Diseases in Global Health

Tel: +44 (0)161 291 5818


Education and Research Centre
University Hospital of South Manchester
Southmoor Road
M23 9LT

Fax: +44 (0) 161 291 5806

Telephone: +44 (0) 161 291 5811 (Secretary)




  • Practising physician at one of Manchester's University Hospitals with expertise in fungal infections, particularly aspergillosis, antifungal resistance, the treatment of fungal infection and infection in the immunocompromised patient
  • Graduate of Guys Hospital London in 1980, with training in medicine, paediatrics, gastroenteroloy, haematology, infectious diseases and clinical microbiology, including a 3 year fellowship at Stanford University with Professor David Stevens (1987-1990)
  • Author of >450 research papers and chapters, mostly on fungal disease, resistance in fungi and treatment of fungal infection.
  • Co-author of ‘Medicine' with Professor Paul O'Neil and Dr Tim Dornan, an undergraduate textbook of medicine now in its third edition (2008).
  • Google H-index of 100
  • Personal citation index of >47,500 
  • Research grant income to Manchester University >£22M since 1990
  • Director of National Aspergillosis Centre,  based at University Hospital of South Manchester, Wythenshawe Hospital.
  • Co-ordinator of the International Genome Sequencing project for Aspergillus fumigatus (funded by NIH, Wellcome Trust and Spanish government) 1997-2005
  • Founder and Editor of Aspergillus website (1998-)
  • Consultant (current or past) to multiple pharmaceutical companies with regard to antifungal drug discovery including Merck, Pfizer, Schering Plough, Oxford Glycosciences and Astellas.
  • Founder of F2G Ltd, an antifungal drug discovery company spun out from Manchester University (1998-).
  • Founder and Chief Medical Officer of Myconostica (acquired by Trinity Biotech), developing and commercialising molecular diagnostics for fungal disease (2006-2011).
  • Listed in Who's Who in the World since 1996/7 Listed in Who's Who in Healthcare since 1997 Listed in Who's Who in Science and Technology since 2005, in Who's Who 2013-
  • Chairman of several international conferences (Trends in Invasive Fungal Infection (x3 1993, 1997 and 1999; Advances against Aspergillosis x6 2004, 2006, 2008, 2010 and 2012, 2014, 2016: Aspergillus Genetics and Genomes Focus Meeting 2004, and other smaller meetings) and sessions at major congresses.
  • MacFarlane Burnett Lecturer to the Australasian Society of Infectious Diseases, 2005.

  • Keynote plenary speaker at the European Conference on Clinical Microbiology and Infectious Diseases, 2008; International Society for Human and Animal Mycology, Tokyo, 2009; Asian Mycological Congress, Beijing, 2013; Trends in Medical Mycology, Copenhagen, 2013, International Union of Microbiological Societies, Montreal, 2014.

  • Director of the Leading International Fungal Education (LIFE) program on behalf of the Fungal Infection Trust, 2012 –

  • Founding President of Global Action Fund for Fungal Infections (GAFFI) in Geneva, 2013 - .




Principal Investigator, Manchester Fungal infection Group

Director, National Aspergillosis Centre, based at University Hospital of South Manchester.

Managing Editor, The Aspergillus Website

President, Global Action Fund for Fungal infections (GAFFI)


Social Responsibility

Leading International Fungal Education (LIFE) at

Global Action Fund for Fungal Infections at


Most teaching involves project options students and postgaduate research students.

Externally, expertise on chronic and allergic aspergillosis and the treatment of fungal disease is shared with doctors all over the world.

Leading Fungal infection International (LIFE) is one of many resources available worldwide.